Literature DB >> 24717839

Transporter-mediated prostaglandin E₂ elimination across the rat blood-brain barrier and its attenuation by the activation of N-methyl-D-aspartate receptors.

Shin-ichi Akanuma1, Takanori Higuchi, Hideyuki Higashi, Go Ozeki, Masanori Tachikawa, Yoshiyuki Kubo, Ken-ichi Hosoya.   

Abstract

Prostaglandin (PG) E2 is involved in neuroinflammation and neurotoxicity, and the cerebral PGE2 concentration is increased in neurodegenerative diseases. Because the intracerebral concentration of L-glutamate (L-Glu) is reported to be also elevated in neurodegenerative diseases, it has been proposed that L-Glu affects PGE2 dynamics in the brain, and thus exacerbates neural excitotoxicity. The purpose of this study was to investigate the effect of intracerebral L-Glu on PGE2 elimination across the blood-brain barrier (BBB) in rats by using the intracerebral microinjection technique. [(3)H]PGE2 injected into the cerebral cortex was eliminated from the brain in rats, and the apparent brain-to-blood [(3)H]PGE2 efflux clearance was found to be 60.1 µL/(min·g brain). Intracerebral pre-administration of 50 mM L-Glu significantly inhibited [(3)H]PGE2 elimination across the BBB and this L-Glu-induced inhibition was abolished by co-administration of an intracellular Ca(2+) chelator. The intracellular Ca(2+) concentration is reported to be increased via N-methyl-d-aspartate (NMDA)-type L-Glu receptors (NMDAR) and [(3)H]PGE2 elimination was attenuated by intracerebral pre-administration of a mixture of NMDA and D-serine. Moreover, the co-administration of antagonists of NMDAR with L-Glu abolished the attenuation of PGE2 elimination induced by intracerebral L-Glu administration. These results suggest that L-Glu attenuates BBB-mediated PGE2 elimination via NMDAR-mediated processes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24717839     DOI: 10.2133/dmpk.dmpk-14-rg-004

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  3 in total

1.  Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier.

Authors:  Ryuta Jomura; Shin-Ichi Akanuma; Björn Bauer; Yukiko Yoshida; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2021-02-01       Impact factor: 4.200

2.  Inhibition of human microsomal PGE2 synthase-1 reduces seizure-induced increases of P-glycoprotein expression and activity at the blood-brain barrier.

Authors:  Emma L B Soldner; Anika M S Hartz; Shin-Ichi Akanuma; Anton Pekcec; Henri Doods; Richard J Kryscio; Ken-Ichi Hosoya; Björn Bauer
Journal:  FASEB J       Date:  2019-10-22       Impact factor: 5.834

3.  Inflammation, Obsessive-Compulsive Disorder, and Related Disorders.

Authors:  Jeffrey Meyer
Journal:  Curr Top Behav Neurosci       Date:  2021
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.